A publicly traded Danish medical marijuana operator Stenocare announced Monday the approval of its innovative product, Astrum 10-10, for sale in Norway. This milestone paves the way for more patients to access the benefits of medical cannabis treatment. Astrum 10-10 is expected to become available to patients within the next 30 days.
“Our Astrum 10-10 oil was initially approved for sale in Australia and Germany and we are now proud to add Norway to the list," stated Stenocare CEO Thomas Skovlund Schnegelsberg. "We believe the new Astrum product represents a groundbreaking advancement for the entire medical cannabis industry and Norwegian patients alike. This innovative product directly addresses key challenges with bioavailability in patients, supported by robust data from a pharmacokinetic study in dogs that validates its benefits. With this milestone, Stenocare is firmly positioned as a first-mover in the next generation of medical cannabis oil products, poised to revolutionise the market.”
Stenocare has been collaborating with partners over the last five years to develop and test next-generation medical marijuana oil products. It is now ready to present its patented product to Norwegian patients.
Officially named "Astrum 10-10 Oil Stenocare," the product contains 10 mg/ml THC and 10 mg/ml CBD in a 30 ml bottle.
Read Also: Danish Cannabis Company Stenocare To Launch ‘Innovative’ Medical Marijuana Oil In Germany
Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter here. If you're serious about the business, you can't afford to miss out.
Astrum Oil Bioavailability
The Stenocare Astrum oil is based on technology designed to enhance the bioavailability of cannabinoids in the patient's bloodstream. This innovation aims to address a common challenge in medicine dosing by ensuring consistent uptake of active ingredients into the blood. With the Astrum product, Stenocare has successfully completed a pharmacokinetic (PK) study in dogs, documenting two critical parameters in the lymphatic system that can significantly improve bioavailability:
- Parameter 1 – uptake in the blood: According to the PK study in dogs, Astrum improves blood uptake by a factor of 2.6 compared to a reference MCT-oil product on the market. When patients use traditional MCT-oil-based medical cannabis, the metabolism often reduces the uptake of cannabinoids in the body. As a result, a highly variable and often limited amount of active ingredients (i.e., cannabinoids) reaches the patient with a therapeutic effect. This creates difficulties in prescribing a consistent dosage to patients.
- Parameter 2 – time to maximum effect: The PK study showed that the Stenocare Astrum product reduces the time from dosing to maximum effect from 2-4 hours to just 1 hour, providing a more consistent experience for patients.
Read Next:
Photo: Courtesy of Tinnakorn jorruang via Shutterstock
